ClinVar Miner

Submissions for variant NM_000551.3(VHL):c.492G>C (p.Gln164His) (rs1352275281)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000756902 SCV000884876 likely pathogenic not provided 2018-05-16 criteria provided, single submitter clinical testing The VHL c.492G>C; p.Gln164His variant has been described in several individuals affected with pheochromocytoma and/or paraganglioma (Bauters 2003, Buffet 2012, McInerney-Leo 2014) and is observed on only 2 alleles in the Genome Aggregation Database. The glutamine at codon 164 is highly conserved but computational algorithms (PolyPhen-2: damaging, SIFT: tolerated) are inconclusive on the effect of this variant on protein structure and/or function. However, this variant occurs in a region that is critical for binding to elongin B and elongin C (Kishida 1995, Ohh 1999). Additionally, another variant at this codon (c.491A>G; p.Gln164Arg) has been reported in individuals affected with pheochromocytoma and/or paraganglioma and is considered pathogenic (Buffet 2012, Sovinz 2010). Based on available information, this variant is considered likely pathogenic. References: Bauters C et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet. 2003 Jun;40(6):e75. Buffet A et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012 May;44(5):359-66. Kishida T et al. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res. 1995 Oct 15;55(20):4544-8. McInerney-Leo A et al. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf). 2014 Jan;80(1):25-33. Ohh M et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999 Dec;104(11):1583-91. Sovinz P et al. Pheochromocytoma in a 2.75-year-old-girl with a germline von Hippel-Lindau mutation Q164R. Am J Med Genet A. 2010 Jul;152A(7):1752-5.
Ambry Genetics RCV001023281 SCV001185134 likely pathogenic Hereditary cancer-predisposing syndrome 2020-05-29 criteria provided, single submitter clinical testing The p.Q164H variant (also known as c.492G>C), located in coding exon 3 of the VHL gene, results from a G to C substitution at nucleotide position 492. The glutamine at codon 164 is replaced by histidine, an amino acid with highly similar properties. This alteration has been reported in a 47-year-old female with an abdominal paraganglioma (PGL) and a family member with unilateral pheochromocytoma (PCC) at age 39 (Bauters C et al. J. Med. Genet. 2003 Jun;40:e75). In addition, a different nucleotide change at the same position (VHL c.492G>T) causing the same amino acid change has been identified in a patient with capillary retinal angioma (Kreusel KM et al. Can. J. Ophthalmol. 2007 Apr;42:251-5; McInerney-Leo AM et al. Clin. Endocrinol. (Oxf) 2014 Jan;80:25-33) and several patients with either PGL or PCC (Meyer-Rochow GY et al. J. Surg. Res. 2009 Nov;157:55-62; Buffet A et al. Horm. Metab. Res. 2012 May;44:359-66). Internal structural analysis indicates this alteration disrupts the fold of the elongin binding domain of VHL (Ambry internal data; Van Molle I et al. Chem. Biol. 2012 Oct;19:1300-12). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Invitae RCV001382402 SCV001581154 pathogenic Erythrocytosis, familial, 2; Von Hippel-Lindau syndrome 2020-03-04 criteria provided, single submitter clinical testing This sequence change replaces glutamine with histidine at codon 164 of the VHL protein (p.Gln164His). The glutamine residue is highly conserved and there is a small physicochemical difference between glutamine and histidine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with clinical features of von Hippel-Lindau syndrome (PMID: 19215943, 12807974, 24102379). ClinVar contains an entry for this variant (Variation ID: 618485). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: Deleterious; PolyPhen-2: Probably Damaging; Align-GVGD: Class C0). A different variant (c.492G>T) giving rise to the same protein effect observed here (p.Gln164His) has been determined to be pathogenic (PMID: 17392848, 29891534, 24102379, 22517557, Invitae). This suggests that this variant is also likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.